Aptevo Therapeutics (NASDAQ:APVO) posted its quarterly earnings results on Tuesday. The biotechnology company reported ($1.92) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($1.22) by ($0.70), Fidelity Earnings reports.
NASDAQ:APVO traded down $2.21 during mid-day trading on Thursday, hitting $28.31. The company had a trading volume of 53,124 shares, compared to its average volume of 63,692. Aptevo Therapeutics has a fifty-two week low of $3.06 and a fifty-two week high of $60.00. The business’s fifty day moving average is $34.11 and its two-hundred day moving average is $28.85. The company has a debt-to-equity ratio of 11.44, a quick ratio of 4.13 and a current ratio of 4.13. The firm has a market cap of $123.97 million, a P/E ratio of -1.87 and a beta of 7.47.
Separately, Zacks Investment Research lowered shares of Aptevo Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, January 8th.
Aptevo Therapeutics Inc, a clinical-stage biotechnology company, engages in the discovery, development, commercialization, and sale of novel oncology and hematology therapeutics in the United States. Its marketed product includes IXINITY, a coagulation factor IX therapeutic indicated in adults and children 12 years of age and older with hemophilia B for control and prevention of bleeding episodes, and management of bleeding during operations.
Featured Article: Outstanding Shares, Buying and Selling Stocks
Receive News & Ratings for Aptevo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptevo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.